Vincristine, Carboplatin, and Etoposide or Observation Only in Treating Patients Who Have Undergone Surgery for Newly Diagnosed Retinoblastoma

Trial ID or NCT#

NCT00335738

Status

not recruiting iconNOT RECRUITING

Purpose

This phase III trial is studying vincristine, carboplatin, and etoposide to see how well they work compared to observation only in treating patients who have undergone surgery for newly diagnosed retinoblastoma. Drugs used in chemotherapy, such as vincristine, carboplatin, and etoposide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) after surgery may kill any tumor cells that remain after surgery. Sometimes, after surgery, no additional treatment is needed for the tumor until it progresses. In this case, observation may be sufficient.

Official Title

A Study of Unilateral Retinoblastoma With and Without Histopathologic High-Risk Features and the Role of Adjuvant Chemotherapy

Eligibility Criteria

Ages Eligible for Study: Younger than 6 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No

Investigator(s)

Neyssa Marina

Contact us to find out if this trial is right for you.

Contact

Cancer Clinical Trials Office
650-498-7061